Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
500 nn » 500 nm (Expand Search), 500 ng (Expand Search), 500 ns (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
500 nn » 500 nm (Expand Search), 500 ng (Expand Search), 500 ns (Expand Search)
-
81
-
82
Increases in 1,5-anhydrosorbitol and decreases in ascorbic acid following RYGB.
Published 2013“…B) For ascorbic acid, the ANOVA model did not detect group-specific changes over time (no group:time interaction), but indicated significant decreases from T0 to T6 in both groups. Overall, 1,5-anhydrosorbitol and ascorbic acid were significantly different at each time point between OB and OB/D subgroups (p<0.01, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0007905#pone-0007905-t002" target="_blank"><b>TABLE 2</b></a>).…”
-
83
-
84
-
85
Genetic correlations in viral load between single and coinfections of CrPV and DCV.
Published 2023Subjects: -
86
Interspecific correlations in viral load between single and coinfections of CrPV and DCV.
Published 2023Subjects: -
87
-
88
-
89
-
90
Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T...
Published 2022“…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC<sub>(tofacitinib, 0–∞)</sub> and a 9.61-fold increase of colonic AUC<sub>(tofacitinib, 0–12h)</sub>, compared with tofacitinib at a molar equivalent oral dose. …”
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100